Cover

Mechanisms of Epithelial Defense

Editor(s): Kabelitz D. (Kiel) 
Schröder J.-M. (Kiel) 
Table of Contents
Vol. 86, No. , 2005
Section title: Paper
Kabelitz D, Schröder J-M (eds): Mechanisms of Epithelial Defense. Chem Immunol Allergy. Basel, Karger, 2005, vol 86, pp 151-183
(DOI:10.1159/000086659)

γδ T Cells Link Innate and Adaptive Immune Responses

Focus on Human Vγ9/Vδ2 and Vδ1 T Cells

Holtmeier W. · Kabelitz D.
aMedizinische Klinik I., Johann Wolfgang Goethe-Universität, Frankfurt am Main, and bInstitute of Immunology, UK S-H Campus Kiel, Kiel, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

While most T cells use a CD3-associated α/β T cell receptor as antigen recognition structure, a second population of T cells expresses the alternative γ/δ T cell receptor. γ/δ T cells are a minor population in the peripheral blood but constitute a major population among intestinal intraepithelial lymphocytes. Most γ/δ T cells recognize ligands which are fundamentally different from the short peptides that are seen by α/β T cells in the context of MHC class I or class II molecules. Thus, human Vδ2 T cells recognize small bacterial phosphoantigens, alkylamines and synthetic aminobisphosphonates, whereas Vδ1 T cells recognize stress-inducible MHC-related molecules MICA/B as well as several other ligands. At the functional level, γ/δ T cells rapidly produce a variety of cytokines and usually exert potent cytotoxic activity, also towards many tumor cells. In this article, we discuss the role of γ/δ T cells as a bridge between the innate and the adaptive immune system, based on the interpretation that γ/δ T cells use their T cell receptor as a pattern recognition receptor. Our increasing understanding of the ligand recognition and activation mechanisms of γ/δ T cells also opens new perspectives for the development of γ/δ T cell-based immunotherapies.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50